Market Capitalization (Millions $) |
1,584 |
Shares
Outstanding (Millions) |
38 |
Employees |
5,860 |
Revenues (TTM) (Millions $) |
573 |
Net Income (TTM) (Millions $) |
25 |
Cash Flow (TTM) (Millions $) |
-97 |
Capital Exp. (TTM) (Millions $) |
18 |
Taro Pharmaceutical Industries Ltd
Taro Pharmaceutical Industries Ltd is a leading global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter (OTC) drugs for a range of therapeutic areas. Headquartered in Haifa Bay, Israel, Taro has a presence in more than 25 countries across North America, Europe, and Asia-Pacific. Established in 1950, the company has grown to become one of the top 10 generic drug manufacturers in the world.
Taro has a diverse portfolio of products that includes a wide range of topical creams, ointments, and gels; inhalers; tablets and capsules; liquids and pellets; and suspensions. The company's product portfolio spans multiple therapeutic categories, including dermatology, cardiology, gastroenterology, oncology, pediatrics, and urology. Some of its leading products include generic versions of Lotemax (loteprednol etabonate ophthalmic suspension), Ketoconazole Cream 2%, and the Lidocaine Patch 5%.
One of Taro's key strengths is its ability to deliver high-quality, affordable generics to customers around the world. The company has a state-of-the-art manufacturing infrastructure, which includes multiple research and development centers, manufacturing plants, and distribution centers. Taro's manufacturing facilities are located in Israel, Canada, and India, and are equipped with the latest technologies and processes to ensure high quality and efficiency. Its research and development centers are focused on developing new products and enhancing existing ones.
Taro's commitment to quality is reflected in its adherence to strict regulatory standards. The company has several regulatory approvals from the US FDA, Health Canada, and other regulatory agencies around the world. Taro's products are known for their efficacy, safety, and reliability, which has earned the company an enviable reputation in the global pharmaceutical industry.
Taro's success is also attributed to its strong corporate culture that is based on innovation, collaboration, and ethical practices. The company places a high value on its employees and invests in their development and wellbeing. Taro is committed to creating a diverse and inclusive work environment that fosters growth, innovation, and productivity. The company's ethical practices are reflected in its commitment to adhering to strict compliance standards and ensuring the safety and wellbeing of its patients and customers.
In summary, Taro Pharmaceutical Industries Ltd is a leading global pharmaceutical company that delivers high-quality, affordable generics to customers around the world. The company has a diverse portfolio of products, a state-of-the-art manufacturing infrastructure, and a strong commitment to quality, innovation, and ethical practices. Its continued growth and success in the global pharmaceutical industry are a testament to its unwavering commitment to excellence.
Company Address: 14 Hakitor Street Haifa Bay 2624761 NY
Company Phone Number: 345-9000 Stock Exchange / Ticker: NYSE TARO
TARO is expected to report next financial results on June 28, 2024. |
|
|